Clinical Trial Update: Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of vamifeport in adults with HFE-related hereditary hemochromatosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemochromatosis

Drugs mentioned

• Vamifeport (vamifeport)

Snippet

Sponsor: CSL Behring | Conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Phase 2 | Status: RECRUITING